21:1046–1053.16 16. Rubio C, Hill ME, Milan S, et al. Idiopathic pneumonia syndrome after high‐dose chemotherapy for relapsed Hodgkin's disease. Br J Cancer. 1997; 75:1044–1048.
17 17. Majhail NS, Rizzo JD, Lee SJ, et al. Recommended screening and preventive practices for long‐term survivors after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2012; 18:348–371.
18 18. Bhatia S, Armenian SH, Landier W. How I monitor long‐term and late effects after blood or marrow transplantation. Blood. 2017; 130:1302–1314.
19 19. Carpenter PA, Englund JA. How I vaccinate blood and marrow transplant recipients. Blood. 2016; 127:2824–2832.
20 20. Armenian SH, Sun CL, Shannon T, et al. Incidence and predictors of congestive heart failure after autologous hematopoietic cell transplantation. Blood. 2011; 118:6023–6029.
21 21. Bleeker JS, Gertz MA, Pellikka PA, et al. Evaluation of pretransplant factors predicting cardiac dysfunction following high‐dose melphalan conditioning and autologous peripheral blood stem cell transplantation. Eur J Haematol. 2012; 89:228–235.
22 22. Armenian SH, Sun CL, Mills G, et al. Predictors of late cardiovascular complications in survivors of hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2010; 16:1138–1144.
23 23. Chow EJ, Baker KS, Lee SJ, et al. Influence of conventional cardiovascular risk factors and lifestyle characteristics on cardiovascular disease after hematopoietic cell transplantation. J Clin Oncol 2014; 32:191–198.
24 24. Baker KS, Ness KK, Steinberger J, et al. Diabetes, hypertension, and cardiovascular events in survivors of hematopoietic cell transplantation: a report from the bone marrow transplantation survivor study. Blood. 2007; 109:1765–1772.
25 25. Carey RM, Whelton PK. Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Synopsis of the 2017 American College of Cardiology/American Heart Association Hypertension Guideline. Ann Intern Med. 2018; 168:351–358.
26 26. Vaduganathan M, Hirji SA, Qamar A, et al. Efficacy of neurohormonal therapies in preventing cardiotoxicity in patients with cancer undergoing chemotherapy. JACC: CardioOncology. 2019; 1:54–65.
27 27. Clasen SC, Scherrer‐Crosbie M. Applications of left ventricular strain measurements to patients undergoing chemotherapy. Curr Opin Cardiol 2018; 33:493–497.
28 28. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014; 129:S1–45.
29 29. Jaiswal S, Natarajan P, Silver AJ, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med. 2017; 377:111–121.
30 30. Tarella C, Passera R, Magni M, et al. Risk factors for the development of secondary malignancy after high‐dose chemotherapy and autograft, with or without rituximab: a 20‐year retrospective follow‐up study in patients with lymphoma. J Clin Oncol 2011; 29:814–824.
31 31. Kalaycio M, Rybicki L, Pohlman B, et al. Risk factors before autologous stem‐cell transplantation for lymphoma predict for secondary myelodysplasia and acute myelogenous leukemia. J Clin Oncol. 2006; 24:3604–3610.
32 32. Krishnan A, Bhatia S, Slovak ML, et al. Predictors of therapy‐related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors. Blood. 2000; 95:1588–1593.
33 33. Gibson CJ, Lindsley RC, Tchekmedyian V, et al. Clonal hematopoiesis associated with adverse outcomes after autologous stem‐cell transplantation for lymphoma. J Clin Oncol. 2017; 35:1598–1605.
34 34. Bilmon IA, Ashton LJ, Le Marsney RE, et al. Second cancer risk in adults receiving autologous haematopoietic SCT for cancer: a population‐based cohort study. Bone Marrow Transplant. 2014; 49:691–698.
35 35. Sanchez‐Ortega I, Canals C, Peralta T, et al. Thyroid dysfunction in adult patients late after autologous and allogeneic blood and marrow transplantation. Bone Marrow Transplant. 2012; 47:296–298.
36 36. Tauchmanova L, Selleri C, De Rosa G, et al. Endocrine disorders during the first year after autologous stem‐cell transplant. Am J Med 2005; 118:664–670.
37 37. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organization technical report series. 1994; 843:1–129.
38 38. Buckley L, Humphrey MB. Glucocorticoid‐induced osteoporosis. N Engl J Med. 2018; 379:2547–2556.
39 39. Campbell S, Sun CL, Kurian S, et al. Predictors of avascular necrosis of bone in long‐term survivors of hematopoietic cell transplantation. Cancer. 2009; 115:4127–4135.
40 40. Yao S, Smiley SL, West K, et al. Accelerated bone mineral density loss occurs with similar incidence and severity, but with different risk factors, after autologous versus allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2010; 16:11301137.
41 41. Compston JE, McClung MR, Leslie WD. Osteoporosis. Lancet. 2019; 393:364–376.
42 42. Brennan BM, Shalet SM. Endocrine late effects after bone marrow transplant. Br J Haematol. 2002; 118:58–66.
43 43. Schimmer AD, Ali V, Stewart AK, et al. Male sexual function after autologous blood or marrow transplantation. Biol Blood Marrow Transplant. 2001; 7:279–283.
44 44. Loren AW, Chow E, Jacobsohn DA, et al. Pregnancy after hematopoietic cell transplantation: a report from the late effects working committee of the Center for International Blood and Marrow Transplant Research (CIBMTR). Biol Blood Marrow Transplant. 2011; 17:157–166.
45 45. Schimmer AD, Quatermain M, Imrie K, et al. Ovarian function after autologous bone marrow transplantation. J Clin Oncol. 1998; 16:2359–2363.
46 46. Teinturier C, Hartmann O, Valteau‐Couanet D, et al. Ovarian function after autologous bone marrow transplantation in childhood: high‐dose busulfan is a major cause of ovarian failure. Bone Marrow Transplant. 1998; 22:989–994.
47 47. Salooja N, Szydlo RM, Socie G, et al. Pregnancy outcomes after peripheral blood or bone marrow transplantation: a retrospective survey. Lancet. 2001; 358:271–276.
48 48. Hingorani S. Renal complications of hematopoietic‐cell transplantation. N Engl J Med. 2016; 374:2256–2267.
49 49. Choi M, Sun CL, Kurian S, et al. Incidence and predictors of delayed chronic kidney disease in long‐term survivors of hematopoietic cell transplantation. Cancer. 2008; 113:1580–1587.
50 50. Hoffmeister PA, Hingorani SR, Storer BE, et al. Hypertension in long‐term survivors of pediatric hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2010; 16:515–524.
51 51. Cohen EP, Irving AA, Drobyski WR, et al. Captopril to mitigate chronic renal failure after hematopoietic stem cell transplantation: a randomized controlled trial. Int J Radiat Oncol Biol Phys. 2008; 70:1546–1551.
52 52. Jantunen E, Itala M, Siitonen T, et al. Late non‐relapse mortality among adult autologous stem cell transplant recipients: a nation‐wide analysis of 1,482 patients transplanted in 1990‐2003. Eur J Haematol. 2006; 77:114–119.
53 53.
